| Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 20806443 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To perform a meta-analysis to derive a more precise estimation of imatinib treatment for different genotypes of gastrointestinal stromal tumors (GIST). METHODS: Studies were identified by searching PubMed and Embase. Inclusive criteria were patients with exon 9-mutant, exon 11-mutant or wide type (WT) GIST, receiving chemotherapy of imatinib for clinical trial, and efficacy evaluation was cumulative response (CR) including complete response and partial response. The odds ratios (OR) for CR in stem cell factor receptor (KIT) mutation patients vs WT genotype patients, KIT exon 11-mutant genotype patients vs KIT exon 9-mutant genotype patients and KIT exon 9-mutant genotype patients vs WT genotype patients were calculated with 95% confidence interval (CI) for each study as an estimation of the efficacy of imatinib. RESULTS: Five studies including 927 patients were involved in this meta-analysis. The overall OR (KIT group vs WT group) was 3.34 (95% CI: 2.30-4.86, P < 0.00001, P(heterogeneity) = 0.04). The overall OR in KIT exon 11 group vs KIT exon 9 group was 3.29 (95% CI: 2.17-5.00, P < 0.00001, P(heterogeneity) = 0.33). The overall OR in KIT exon 9 group vs WT group was 1.23 (95% CI: 0.73-2.10, P = 0.44, P(heterogeneity) = 0.42). CONCLUSION: Most patients with different genotypes of GIST and KIT exon 11-mutant will benefit from the individualized treatment of imatinib. |
| | |
Authors:
|
Ping Chen; Liang Zong; Wei Zhao; Lei Shi |
Related Documents
:
|
11996473 - The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (cmf) for p... 14512803 - Protective effects of green tea extracts (polyphenon e and egcg) on human cervical lesi... 18551513 - De novo lmna mutations cause a new form of congenital muscular dystrophy. |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Meta-Analysis |
Journal Detail:
|
Title: World journal of gastroenterology : WJG Volume: 16 ISSN: 1007-9327 ISO Abbreviation: World J. Gastroenterol. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-31 Completed Date: 2010-12-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883448 Medline TA: World J Gastroenterol Country: China |
Other Details:
|
Languages: eng Pagination: 4227-32 Citation Subset: IM |
Affiliation:
|
Department of Gastrointestinal Surgery, Subei People's Hospital of Jiangsu Province, Yangzhou 225001, Jiangsu Province, China. chen86ky@126.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use* Drug Resistance, Neoplasm / genetics Exons / genetics Gastrointestinal Stromal Tumors / drug therapy*, genetics Genotype Humans Mutation / genetics Piperazines / therapeutic use* Proto-Oncogene Proteins c-kit / genetics Pyrimidines / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib; EC 2.7.10.1/Proto-Oncogene Proteins c-kit |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence of irritable bowel syndrome in Chinese college and university students assessed using Rom...
Next Document: Agressive inflammatory myofibroblastic tumor of the liver with underlying schistosomiasis: a case re...